NAD-boosting treatment shows no Parkinson's benefit in yearlong trial
2 sources·Updated October 9, 2026
Covered by 2 sources
- News-Medical·8h agoNicotinamide riboside fails to slow progression of early Parkinson’s disease
A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA.
Read at News-Medical → - Medical Xpress·14h agoNAD-boosting treatment shows no Parkinson's benefit in yearlong trial
A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA.
Read at Medical Xpress →